Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65 (FerHem)
The upper and lower gastrointestinal bleeding, not related to portal hypertension, is a common disorder in the elderly. Indeed, in 1996, in a French study, the median age of patients hospitalized for upper gastrointestinal bleeding was 68. During the same period in the studies reported in English the median age was 71. If epidemiological data concerning lower gastrointestinal bleeding are rare, the average age of hospitalized patients varies from 63 to 77 depending on the study. Due to improvement in endoscopic haemostatic procedures and current resuscitation methods, gastrointestinal bleeding prognosis has greatly improved, whereas anaemia related to a bleeding episode remains a frequent complication of gastrointestinal bleeding in elderly patients.
Among elderly patients over 65, the prevalence of anaemia varies from 8 to 44% depending on the criteria used and populations studied. The occurrence of a bleeding episode can either induce anaemia or exacerbate pre-existing anaemia. Physicians in charge of gastrointestinal bleeding are often unaware of anaemic consequences in the elderly patients which can often be serious. Various studies have shown that anaemia increases morbidity and mortality rates in the elderly. Life expectancy is independently significantly lower for anaemic patients over 65, than for non-anaemic subjects. Anaemia is also a risk factor for the occurrence of cardiovascular and neurological complications, impairment in cognitive function and increased risk of falling.
Iron deficiency and anaemia induced by bleeding episodes in patients over 65 hospitalized for upper or lower gastrointestinal bleeding should be corrected rapidly and effectively. Currently, the cost and risks of infection or cardiovascular-related complications of transfusions lead to limiting red blood cell transfusion with a goal average of 9 g/dL haemoglobin. It is also necessary to develop alternatives to massive transfusions. The correction of iron deficiency promotes erythropoiesis and can quickly correct anaemia.
In clinical practice, the effectiveness of iron intake by the oral route is limited by the frequent occurrence of significant gastrointestinal side effects that limit patient compliance and limited absorption necessitating prolonged treatment to correct iron deficiency.
The black colour of stools caused by taking oral iron supplements also makes it difficult to detect a possible recurrence of bleeding after hospitalization.
The prescription of intravenous iron seems more suitable for a rapid and complete correction of iron deficiency after gastrointestinal bleeding. The main objective of our study is to evaluate efficacy of intravenous iron for the correction of anaemia, measured by haemoglobin at week 6 (W6) in patients aged over 65, after gastrointestinal bleeding. Secondary objectives were to assess the speed of anaemia correction, the tolerance of intravenous iron supplementation, the rate of re-hospitalization within 6 months after discharge and patients quality of life. This is a prospective multicenter randomized study versus placebo. After obtaining informed consent, all patients aged over 65 admitted with upper or lower gastrointestinal bleeding, with successful outcome, not related to portal hypertension, responsible for persistent anaemia (definition: Hb < 11 g / dL) after hospitalization will be included in the study. Patients will be treated for their bleeding event in the usual manner of each centre with target for transfusion of 9 g / dL haemoglobin. The absence of external bleeding and haematocrit and/or constant haemoglobin levels will be considered as the end of bleeding.
Day 1 was arbitrarily defined as the day the patient left hospital. The protocol at Day - 1 included: obtaining informed consent of the patient, determination of iron and ferritin blood levels and complete blood count. and randomization intravenous iron injection , (Ferinject) versus Placebo. Intravenous iron injection will be performed at Day 0. A complete blood count will be performed at week 6 and month 6. Patients will be reviewed in consultation at week 6 and at month 6 to obtain related intercurrent events and assess their quality of life.
The results of this study could lead to changes in the care of older patients hospitalized for gastrointestinal bleeding.
Drug: Ferinject 1000 mg
Drug: Sodium chlorure 0,9 %
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65|
- Haemoglobin level [ Time Frame: Week 6 ] [ Designated as safety issue: No ]
- Assessment of the tolerance of intravenous iron supplementation [ Time Frame: Day 0 ] [ Designated as safety issue: Yes ]Number of Adverse Event (AE) and Serious Adverse Event(SAE) occurence.
- Assessment of the tolerance of intravenous iron supplementation [ Time Frame: Week 6 ] [ Designated as safety issue: Yes ]Number of Adverse Event (AE) and Serious Adverse Event(SAE) occurence.
- re-hospitalization rate [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Experimental: Ferinject 1000 mg
Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
|Drug: Ferinject 1000 mg|
Placebo Comparator: Placebo
Intravenous administration of 250 ml of sodium chlorure 0.9 %
|Drug: Sodium chlorure 0,9 %|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01690585
|Contact: Julien BLOT||+33232888265||julien.blot@chu-rouen.Fr|
|Amiens, France, 80054|
|Principal Investigator: Jean L DUPAS, Pr|
|CHU de Caen||Recruiting|
|Caen, France, 14000|
|Principal Investigator: DAO, Pr|
|CH de Vendée||Recruiting|
|La Roche sur Yon, France, 85000|
|Principal Investigator: Guillaume MEDINGER, Dr|
|CH Le Mans||Recruiting|
|Le Mans, France, 72037|
|Principal Investigator: Bruno BOUR, Dr|
|CHI le Raincy Montfermeil||Recruiting|
|Le raincy, France, 93370|
|Principal Investigator: Stéphane NAHON, Dr|
|GH du havre||Not yet recruiting|
|Montivilliers, France, 76290|
|Principal Investigator: Jean L TRANVOUEZ, Dr|
|CH de Montélimar||Recruiting|
|Montélimar, France, 26216|
|Principal Investigator: Bernard NALET, Dr|
|CHU de Nice||Recruiting|
|Nice, France, 06202|
|Principal Investigator: Xavier HEBUTERNE, Pr|
|Orléans, France, 45067|
|Principal Investigator: Jean L LEGOUX, Dr|
|CHU de Pau||Not yet recruiting|
|Pau, France, 64046|
|Principal Investigator: Ramuntcho AROTCARENA, Dr|
|CHU de Rennes||Not yet recruiting|
|Rennes, France, 35033|
|Principal Investigator: Jean F BRETAGNE, Pr|
|CHU de Rouen||Recruiting|
|Rouen, France, 76031|
|Contact: Eric LEREBOURS, Pr +33232888101 email@example.com|
|Contact: Julien BLOT +33232888265 julien.blot@chu-rouen.Fr|
|Principal Investigator: Guillaume SAVOYE, Pr|
|CH de Valenciennes||Recruiting|
|Valenciennes, France, 59032|
|Principal Investigator: Rachida BOUBCHIR, Dr|
|Principal Investigator:||Guillaume SAVOYE, Pr||UH Rouen|